BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31142661)

  • 1. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
    Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
    Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
    Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
    Tang W; Ramasamy K; Pillai SMA; Santhamma B; Konda S; Pitta Venkata P; Blankenship L; Liu J; Liu Z; Altwegg KA; Ebrahimi B; Pratap UP; Li X; Valente PT; Kost E; Sareddy GR; Vadlamudi RK; Nair HB; Tekmal RR; Viswanadhapalli S
    Cell Death Discov; 2021 Aug; 7(1):216. PubMed ID: 34400617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting LIF/LIFR signaling in cancer.
    Viswanadhapalli S; Dileep KV; Zhang KYJ; Nair HB; Vadlamudi RK
    Genes Dis; 2022 Jul; 9(4):973-980. PubMed ID: 35685476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
    Li M; Viswanadhapalli S; Santhamma B; Pratap UP; Luo Y; Liu J; Altwegg KA; Tang W; Liu Z; Li X; Ebrahimi B; Yan H; Zou Y; Konda S; Sareddy GR; Xu Z; Chen Y; Rao MK; Brenner AJ; Kaklamani VG; Tekmal RR; Ahmed G; Raj GV; Nickisch KJ; Nair HB; Vadlamudi RK
    Commun Biol; 2021 Oct; 4(1):1235. PubMed ID: 34716410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
    Ebrahimi B; Viswanadhapalli S; Pratap UP; Rahul G; Yang X; Pitta Venkata P; Drel V; Santhamma B; Konda S; Li X; Sanchez ALR; Yan H; Sareddy GR; Xu Z; Singh BB; Valente PT; Chen Y; Lai Z; Rao M; Kost ER; Curiel T; Tekmal RR; Nair HB; Vadlamudi RK
    NPJ Precis Oncol; 2024 May; 8(1):118. PubMed ID: 38789520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.
    Halder S; Parte S; Kshirsagar P; Muniyan S; Nair HB; Batra SK; Seshacharyulu P
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188737. PubMed ID: 35680099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
    Blankenship L; Pratap UP; Yang X; Liu Z; Altwegg KA; Santhamma B; Ramasamy K; Konda S; Chen Y; Lai Z; Zheng S; Sareddy GR; Valente PT; Kost ER; Nair HB; Tekmal RR; Vadlamudi RK; Viswanadhapalli S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
    Dhingra K; Sahin A; Emami K; Hortobagyi GN; Estrov Z
    Breast Cancer Res Treat; 1998 Mar; 48(2):165-74. PubMed ID: 9596488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
    Bian SB; Yang Y; Liang WQ; Zhang KC; Chen L; Zhang ZT
    Ann N Y Acad Sci; 2021 Jan; 1484(1):74-89. PubMed ID: 32827446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential stimulation-induced receptor localization in lipid rafts for interleukin-6 family cytokines signaling through the gp130/leukemia inhibitory factor receptor complex.
    Port MD; Gibson RM; Nathanson NM
    J Neurochem; 2007 May; 101(3):782-93. PubMed ID: 17448148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.
    Di Giorgio C; Marchianò S; Marino E; Biagioli M; Roselli R; Bordoni M; Bellini R; Urbani G; Zampella A; Distrutti E; Donini A; Graziosi L; Fiorucci S
    Front Oncol; 2022; 12():939969. PubMed ID: 35847866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
    Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
    J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.
    Zhang W; Shi X; Chen R; Zhu Y; Peng S; Chang Y; Nian X; Xiao G; Fang Z; Li Y; Cao Z; Zhao L; Liu G; Sun Y; Ren S
    Mol Ther; 2020 Nov; 28(11):2473-2487. PubMed ID: 32592689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of cytokine signaling through leukemia inhibitory factor receptor (LIFR)/gp130 attenuates ischemic brain injury in rats.
    Suzuki S; Yamashita T; Tanaka K; Hattori H; Sawamoto K; Okano H; Suzuki N
    J Cereb Blood Flow Metab; 2005 Jun; 25(6):685-93. PubMed ID: 15716858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness.
    Streitfeld WS; Dalton AC; Howley BV; Howe PH
    Cancer Biol Ther; 2023 Dec; 24(1):2271638. PubMed ID: 37927213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma.
    Hall BR; Cannon A; Thompson C; Santhamma B; Chavez-Riveros A; Bhatia R; Nair HB; Nickisch K; Batra SK; Kumar S
    Genes Cancer; 2019 Feb; 10(1-2):1-10. PubMed ID: 30899415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
    Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
    Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells.
    Sun Q; Wang J; Xiong J; Yang L; Liu H
    Oncol Rep; 2011 Aug; 26(2):399-404. PubMed ID: 21567092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer.
    Liu YN; Chen WY; Liu MK; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Wang WH; Abou-Kheir W; Wen YC
    Mol Oncol; 2024 Jun; 18(6):1665-1686. PubMed ID: 38381121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.